Status:
COMPLETED
A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The objective of this study is to evaluate the efficacy, safety and tolerability for pregabalin using a flexible, optimized dose schedule compared to placebo in relieving the symptoms of neuropathic p...
Eligibility Criteria
Inclusion
- Chinese outpatient of age 18 to 75
- At screening and baseline, a score of greater than 40 mm on the visual log scale of SF-MPQ
Exclusion
- Neurologic disorders unrelated to neuropathic pain, which in the opinion of the investigator, might impair the assessment of pain
- Serum creatinine clearance greater than 60 ml/min
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
309 Patients enrolled
Trial Details
Trial ID
NCT00301223
Start Date
February 1 2006
End Date
September 1 2007
Last Update
January 22 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beijing, China
2
Pfizer Investigational Site
Cheng Du Si Chaun, China
3
Pfizer Investigational Site
Guangzhou, China
4
Pfizer Investigational Site
Nan Jing, Jiang Su, China